By 2025, the specialty control plasma market is expected to exceed USD 11,052.8 million according to experts. They anticipate it will expand to USD 20,553.7 million during the year 2035. 6.4% annual growth (year over year). Unprecedented growth in these tests has been attributed to increased awareness of disease early identification, greater regulation of lab quality, and advances in plasma technology.
The specialty control plasma market looks set to grow steadily from 2025 to 2035. This is due to more people having blood problems, better diagnostic tech, and greater need for quality checks in labs. Specialty control plasma is key for checking if blood tests are correct, and those tests are vital for spotting hemophilia, clots, and other blood issues. More use of automated and fast diagnostic systems also boosts the market’s growth.
Market Metrics
| Metric | Value |
|---|---|
| Market Size (2025E) | USD 11,052.8 Million |
| Market Value (2035F) | USD 20,553.7 Million |
| CAGR (2025 to 2035) | 6.4% |
Explore FMI!
Book a free demo
North America leads the specialty control plasma market. This is due to a strong healthcare system, high rates of diagnostic tests, and many key market players. The United States is at the forefront with its advanced labs, strict rules for quality control in diagnostics, and more cases of blood disorders like hemophilia and thrombophilia. The market grows more with the rise in point-of-care tests and more money put into healthcare research.
Europe grabs a big chunk of the specialty control plasma market, backed by a focus on good lab tests and tight rules about clinical testing. Germany, the UK, and France lead in using specialty control plasma thanks to better knowledge of early disease spotting and more cases of blood issues. The EU stresses lab quality and surety, boosting the need for top-notch control tools, which helps the market grow more.
The Asia-Pacific area is set to see the quickest growth, driven by more funds in healthcare, more diagnostic tests, and better awareness of blood disorders. China, Japan, and India see high need for specialty plasma because labs are growing, healthcare is getting better, and many people have long-term health issues needing frequent blood tests. Also, efforts by governments to improve lab standards and certification help boost the market in this area.
High Cost and Limited Accessibility in Developing Regions
The challenge in the specialty control plasma market is the cost of quality control materials. In acquiring acquired coagulation testing solutions and quality control (QC) capabilities, a sophisticated laboratory setup is needed which most likely does not exist within low income countries.
As a result, specialized it is expensive for small laboratories to achieve the high level of quality diagnostic accuracy necessary for regulated marketplaces. Especially with small independent laboratories dealing with lower patient volume resulting limitations on their test menu capacity.
Technological Advancements and AI-Driven Laboratory Automation
By incorporating and implementing artificial intelligence (AI) and automation into laboratory diagnostics, a growth opportunity is offered for the specialty control plasma market. The AI-powered algorithm improves the accuracy of the tests, the workflow efficiency, and reduces manual errors in coagulation testing.
The development of novel control plasma products with prolonged stability and improved performance characteristics is another factor responsible for market expansion. Finally, the growth of remote diagnostics and cloud-based laboratory management systems creates further market opportunities, especially in developing markets.
The specialty control plasma market grew steadily from 2020 to 2024. This is due to more cases of bleeding disorders, a high need for good tests, and better lab machines. Labs use specialty control plasma to check bleeding tests are accurate. This makes it very important in testing for diseases.
In the forecast years i.e. 2025 to 2035, the growth of the market is anticipated to flourish on account of the surging prevalence of blood borne disorders, evolution of technological innovations in the testing methods, and the increasing implementation of point-of-care (POC) testing. Moreover, strict regulatory requirements and the need for high-precision quality control substances will remain significant in shaping market dynamics.
Market Shifts: 2020 to 2024 vs. 2025 to 2035
| Market Shift | 2020 to 2024 |
|---|---|
| Regulatory Landscape | Compliance with basic FDA and CE guidelines. |
| Technological Advancements | Improvements in plasma stability and extended shelf-life. |
| Industry Applications | Primarily used in hospitals and diagnostic labs. |
| Automation & AI Integration | Basic automation for sample handling. |
| Sustainability & Packaging | Standard vial packaging and cold chain requirements. |
| Market Growth Drivers | Growth driven by increasing coagulation disorder cases. |
| Market Shift | 2025 to 2035 |
|---|---|
| Regulatory Landscape | Stricter global regulatory frameworks for precision diagnostics. |
| Technological Advancements | Enhanced formulations with synthetic and recombinant plasma alternatives. |
| Industry Applications | Expansion into home-based testing and decentralized diagnostics. |
| Automation & AI Integration | AI-driven predictive analytics and automated quality control systems. |
| Sustainability & Packaging | Development of eco-friendly, room-temperature stable plasma solutions. |
| Market Growth Drivers | Increased focus on personalized medicine and targeted diagnostics. |
The specialty control plasma market in the USA is on the rise. This is because there are more coagulation issues now, a higher need for quality tests in labs, and new hemostasis test methods. The FDA watches over plasma products to keep them safe and useful for tests.
Some trends to note are more use of automatic machines in testing, a rise in freeze-dried and stable plasma, and more point-of-care tests. More cases of blood problems, like hemophilia and thrombophilia, also add to the need for specialty control plasma.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 6.5% |
The specialty control plasma market in the UK is growing. There are more government efforts in healthcare diagnostics, more cases of coagulation problems, and more focus on lab quality. The MHRA is in charge of plasma product approval and safety.
Market trends show higher demand for multi-control plasmas, more use of automated hemostasis analyzers, and more focus on personalized medicine for managing coagulation disorders. Also, the growth of clinical labs and diagnostic centers is helping the market expand.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 6.2% |
The specialty control plasma market in the European Union is growing because of strict rules for clinical tests, more cases of blood clots, and greater need for accurate lab testing. The European Medicines Agency (EMA) and In Vitro Diagnostic Regulation (IVDR) make sure specialty control plasma products meet these rules and are safe.
Germany, France, and Italy help the market grow a lot. This is because they have strong test centers, invest a lot in research, and use external quality check (EQA) programs more and more. The market also grows due to the rising and growing awareness of early blood disorder spotting and tracking.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union (EU) | 6.3% |
The market for specialty control plasma in Japan is growing steadily. This growth is driven by the aging population, more cases of blood disorders, and better diagnostic tools. The PMDA is in charge of the quality and effectiveness of these plasma products for clinical use.
Key trends show more use of new tests for blood issues, more attention on accurate control materials, and a need for special plasma for uncommon blood problems. Moreover, Japan's strong healthcare system and precision medicine are boosting market growth.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 6.5% |
South Korea's market for specialty control plasma is on the rise. This growth is fueled by higher spending on healthcare, more labs using automation, and government backing for better lab quality control. The Ministry of Food and Drug Safety (MFDS) makes sure rules are followed and products are safe in this field.
Trends show a leaning towards budget-friendly and long-lasting plasma controls. There's also a surge in demand for external quality checks and more money going into top-notch coagulation analyzers. More clinical and hospital labs are popping up, which also help the market grow.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 6.4% |
The specialty control plasma market is projected to experience significant growth and is forecasted to witness exceptional expansion due to the rising prevalence of coagulation disorders, increasing adoption of plasma-derived therapies, and technological advancements in diagnostic testing.
Based on plasma composition, the most noteworthy segment of this market is factor VIII concentrate and the most significant applications of this market is coagulation disorders owing to the growing need for effective treatment and management of bleeding disorders.
Market Share by Type (2025)
| Type | Market Share (2025) |
|---|---|
| Factor VIII Concentrate | 55.0% |
Hemophilia A results from a lack of the clotting factor VIII and Factor VIII concentrate is an important component in its treatment. Demand for high-quality Factor VIII concentrates is being driven by the increasing incidence of this condition alongside advances in recombinant and plasma-derived therapies. The Market is being propelled at a Robust Growth rate by several factors such as increasing rates of diagnosis, broader access to hemophilia treatment, and technological innovations in plasma fractionation.
Novel approaches in hemophilia therapy like long-acting agents, recombinant therapies and gene therapy are enhancing clinical outcomes. Yet, difficulties like high production costs, supply chain obstacles, and complicated regulatory mandates continue. Synthetic Factor VIII, newer recombinant clotting factor products, and AI-enabled precision diagnostics are anticipated to improve access and reduce cost across the market.
Market Share by Application (2025)
| Application | Market Share (2025) |
|---|---|
| Coagulation Disorders | 60.0% |
On the basis of application, the specialty control plasma market is segmented into coagulation disorders, infectious diseases, and others, where coagulation disorders constitute the largest application segment in the Specialty Control Plasma Market and are currently the most common applications for Specialty Control Plasma due to the increasing incidence of hemophilia, von Willebrand disease, and other clotting deficiencies.
Additional factor contributing to the market growth includes the increasing demand for specialty plasma products in diagnostics, transfusion therapy, and research applications. Major drivers of the market include government-backed regulations for the management of rare disease, increased investment in the plasma fractionation facilities, and development of next-generation clotting factors.
The trajectory of the market is also being influenced by advancements in AI-driven coagulation assessment, recombinant technology, and custom plasma products. On the other hand, the high cost of treatments, a shortage of donor plasma supply and strict regulatory frameworks are the major challenges.
Specialty control plasma market is yet another good market segment, as it caters to the various control plasma for diagnostic use with excellent performance and qualitative aspects, widespread availability, is the dominating subsector in the Specialty Control Plasma Market.
Coagulation testing, clinical diagnostics, and quality control all depend on the availability of specialty control plasma for accuracy. Growth of market is primarily attributed to the increasing prevalence of coagulation disorders, growing laboratory infrastructure and technological advancements in the hemostasis testing. Includes innovations like lyophilized plasma controls, extended shelf-life formulations and automation-friendly solutions.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Siemens Healthineers | 18-22% |
| Thermo Fisher Scientific | 14-18% |
| Bio-Rad Laboratories | 12-16% |
| Werfen (Instrumentation Laboratory) | 10-14% |
| Stago Group | 6-10% |
| Other Companies (combined) | 30-40% |
| Company Name | Key Offerings/Activities |
|---|---|
| Siemens Healthineers | In 2024, put out better freeze-dried plasma for longer shelf life in blood clot tests. |
| Thermo Fisher Scientific | In 2025, added new automated-friendly specialty plasma checks to its line. |
| Bio-Rad Laboratories | In 2024, brought out better third-party plasma control goods for more lab precision. |
| Werfen (Instrumentation Laboratory) | In 2025, made high-sensitivity plasma checks for special blood tests. |
| Stago Group | In 2024, came out with multi-level special plasma checks for full clot monitoring. |
Key Company Insights
Siemens Healthineers (18-22%)
A leading provider of specialty control plasma, focusing on high-stability formulations for reliable coagulation diagnostics.
Thermo Fisher Scientific (14-18%)
Specializes in automation-ready plasma controls to improve efficiency in high-throughput laboratories.
Bio-Rad Laboratories (12-16%)
Develops high-precision third-party coagulation controls, ensuring diagnostic accuracy and compliance.
Werfen (Instrumentation Laboratory) (10-14%)
Innovates high-sensitivity plasma control materials for advanced hemostasis testing.
Stago Group (6-10%)
Focuses on multi-level specialty control plasma solutions for comprehensive coagulation monitoring.
Other Key Players (30-40% Combined)
Several diagnostic and research-focused companies contribute to market innovations, enhancing specialty control plasma formulations and testing accuracy. These include:
The overall market size for the Specialty Control Plasma Market was USD 11,052.8 Million in 2025.
The Specialty Control Plasma Market is expected to reach USD 20,553.7 Million in 2035.
Increasing prevalence of coagulation disorders, growing demand for quality control in clinical laboratories, advancements in diagnostic technologies, and rising awareness about blood disorder management will drive market growth.
The USA, Germany, China, Japan, and the UK are key contributors.
The coagulation testing segment is expected to lead due to the rising need for accurate monitoring of blood clotting disorders and increased adoption of hemostasis analyzers.
CGRP Inhibitors Market Trends - Growth, Demand & Forecast 2025 to 2035
Indolent Systemic Mastocytosis treatment Market Insights: Size, Trends & Forecast 2025 to 2035
Intraoperative Fluorescence Imaging Market Report - Demand, Trends & Industry Forecast 2025 to 2035
Lung Cancer PCR Panel Market Trends, Growth, Demand & Forecast 2025 to 2035
Polymyxin Resistance Testing Market Analysis by Product, Testing Methods, End User, and Region - Forecast for 2025 to 2035
Procalcitonin (PCT) Assay Market Analysis by Component, Type, and Region - Forecast for 2025 to 2035
Specialty Control Plasma Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
